By tailoring therapies based on specific genetic and molecular profiles—such as targeting DRD2 in tumors with high dopamine receptor expression or employing drugs that modulate specific neurotransmitter systems in PD—treatment strategies can be more precisely aligned with individual patient profiles. This evidence concerns the gene DRD2 and Parkinson disease.